semaj83/ctmatch_classification huggingface dataset:
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 18.0-35.0,  Healthy Healthy Males age 18 to 35 inclusive Body Mass Index 18 to 30 Willing to adhere to prohibitions and restrictions specified in protocol Must give informed consent  Clinically significant abnormal lab values for chemistry, hematology or urinalysis at screening Clinically significant abnormal physical exam, vital signs, or 12-lead EKG at screening Significant history of or current significant medical illness Significant history of or current psychiatric or neurological illness or sleep apnea Participation in another research study involving exposure to ionizing radiation within the last 12 months Any clinically significant MR abnormality which may be relevant to the study Metal implants which are relevant for MR or PET procedures or data History of epilepsy or fits or unexplained blackouts Serology positive for Hepatitis B surface antigen, Hepatitis C antibodies, or HIV antibodies Positive urine screen for drugs of abuse
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 60.0-999.0,  Dementia Alzheimer Disease Dementia, Vascular Sleep Disorders Circadian Dysregulation Age between 60-99 years Clinical diagnosis of Dementia of the Alzheimer's type or Vascular Dementia  Subjects who are too agitated to be able to wear the activity monitors Subjects who are actively suicidal or homicidal or for whom the clinical treatment team considers participation in the study to be unsuitable Subjects with untreated primary sleep disorders Subjects who receive any hypnotic medications during their participation in the study; Subjects who received hypnotic medications in normal doses prior to Partners Human Subjects Research Application Form Filename: Protocol Summary Version Date: June 1, 2005 5 enrollment may participate in the study if they agree to stop receiving hypnotic medications (see above) Subjects who are receiving over the counter sleep aids Subjects who can not commit to abstaining from alcohol use while in the study Subjects with any liver disease Subjects with known anaphylactic reaction or angioedema with Zolpidem CR
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 21.0-55.0,  Generalized Anxiety Disease Healthy males and/or females Age from 21 to 55 (inclusive) BMI ranges from 18 to 30 kg/m2  Previous participation in a PD 332334 study Pregnant or nursing females Hypersensitivity (allergic) to lithium, Neurontin (gabapentin), or Lyrica (pregabalin)
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Acute Schizophrenia Provision of written informed consent by both patient and legal representative A diagnosis of schizophrenia by Chinese Classification and Diagnostic of Mental Disorder, 3rd version (CCMD-3) Male or female, aged 18 to 65 years MOAS total score ³ 10 at both screening and randomization Female patients of childbearing potential must be using a reliable method of contraception and have a negative urine human chorionic gonadotropin (HCG) test at enrolment Able to understand and comply with the requirements of the study  Pregnancy or lactation Any CCMD-3 not defined in the Patients who, in the opinion of the investigator, pose an imminent risk of suicide or a danger to self or others Known intolerance or lack of response to quetiapine fumarate or haloperidol, as judged by the investigator Use of any of the following cytochrome P450 3A4 inhibitors in the 14 days preceding enrolment including but not limited to: ketoconazole, itraconazole, fluconazole, erythromycin, clarithromycin, troleandomycin, indinavir, nelfinavir, ritonavir, fluvoxamine and saquinavir Use of any of the following cytochrome P450 inducers in the 14 days preceding enrolment including but not limited to: phenytoin, carbamazepine, barbiturates, rifampin, St. John's Wort, and glucocorticoids Administration of a depot antipsychotic injection within one dosing interval (for the depot) before randomisation Substance or alcohol dependence at enrolment (except dependence in full remission, and except for caffeine or nicotine dependence), as defined by CCMD-3 Opiates, amphetamine, barbiturate, cocaine, cannabis, or hallucinogen abuse by CCMD-3 within 4 weeks prior to enrolment Medical conditions that would affect absorption, distribution, metabolism, or excretion of study treatment
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Bipolar Disorders Metabolic Complication patients with bipolar disorders (I, II, NOS) diagnosed with DSM-IV age between 18 and 65 Decisional capacity is adequate to provide informed consent or has an authorized appropriate surrogate decision maker. in a syndromal remission state at least for 2 months : CGI BP ≤ 3 patients who have exhibited a clinically significant increase in body weight after starting the administration of their current antipsychotic (ie >7% weight gain)  diagnosis of eating disorder, substance abuse, and psychotic disorder history of neurological and medical illness pregnant or breast feeding women
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Acute Bipolar Depression Outpatients that meet the diagnostic for bipolar disorder I and bipolar disorder II with the most recent episode depressed The total score of the scale that's used for the evaluation of depression (HAM-D) should be ≥20 The total score of the scale that' used for the evaluation of mania (YMRS) should be ≤12  Patients with a current DSM-IV-TR Axis I disorder other than bipolar disorder within 6 months of enrollment. Patients who pose a current serious suicidal or homicidal risk Use of drugs that induce or inhibit the hepatic metabolizing enzymes within 14 days before randomisation Patients who are unable to discontinue all psychoactive medications, including antidepressants, antipsychotics, and mood stabilizers at least 7 days prior to randomisation and consistent with the pharmacokinetics of the drug
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 18.0-55.0,  Bipolar Disorder Schizophrenia Concurrently taking Zyprexa® for a psychiatric indication such as bipolar disorder or schizophrenia Stable body weight (+ 5%) for at least 2 weeks prior to baseline visit No weight loss program participation within past 3 months  Treatment with an atypical Anti-psychotic treatment other than olanzapine with the past 6 months BMI > 40 kg/m2 Use of any dietary supplements related to weight gain or weight loss within past 1 month Use of any medication related to weight or plasma lipid concentration (other than hormonal contraceptives). This includes, but not limited to: antihypertensives, benzodiazepines statins, and psychostimulants Uncontrolled hypertension (SBP >140 or DBP > 90 mmHg) Use of a hypertensive medication Known active alcohol or substance abuse or consumption of > three alcoholic beverages/day Active cardiovascular disease
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Sleep Endometrial Neoplasms Pain be women at least 18 years old have clinical indications of primary endometrioid adenocarcinoma of the endometrium be scheduled for staging surgery by laparotomy under standardized protocols have the ability to communicate in English sufficient for completion of study materials have no neuromuscular/ movement disorders (for actigraphy purposes) have no uncontrolled medical, sleep, endocrine or psychiatric illness (as determined by their attending physician as part of clinical care) have no ongoing use of medication known to affect sleep or wake function (e.g., hypnotics, benzodiazepines, antidepressants, anxiolytics, antipsychotics, decongestants, sedating antihistamines, beta blockers, corticosteroids)  have a history of previous or concomitant cancer have an estimated life expectancy of < 6 months will be admitted to the hospital prior to the day of surgery are unable to complete study measures are unable to provide meaningful informed consent
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 18.0-64.0,  Sleep Initiation and Maintenance Disorders Primary Insomnia Diagnosis of primary insomnia based on DSM-IV (307.42) Written informed consent has been obtained  Patients with sleep apnea syndrome, narcolepsy, presence or suspicion of periodic leg movement or restless leg syndrome Patients with hepatic failure, myasthenia gravis, or hypersensitivity to zolpidem Patients who are known to be current drug or alcohol abuser or likely to concomitantly consume alcoholic beverages (more than 3 times/week) Patients who are pregnant, lactating or intend to become pregnant during the study period Patients who have received antidepressants or anxiolytics will not allow to change the dose or discontinue the previous medication throughout the study Any clinically significant condition, which in the opinion of the investigator makes the patients unsuitable for the trial Participation in any clinical trial within 1 month prior to randomization
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 18.0-76.0,  Cancer Age: 18-76 Current or historical diagnosis of cancer Projected life expectancy of at least one year DSM-IV diagnoses: Acute Stress Disorder, Generalized Anxiety Disorder, Anxiety Disorder due to cancer, Adjustment Disorder with anxious features Any stage of cancer diagnosis  Epilepsy Renal disease Diabetes Abnormal liver function Severe cardiovascular disease Malignant Hypertension Baseline blood pressure must be less than or equal to 140/90 Personal history or immediate family members with schizophrenia, bipolar affective disorder, delusional disorder, schizoaffective disorder or other psychotic spectrum illness Current substance use disorder Medication contraindications: anti-seizures medications, insulin, oral hypoglycemics, clonidine, aldomet, cardiovascular medications, anti-psychotics (first and second generation), anti-depressants and mood stabilizers
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 18.0-60.0,  Bipolar Disorder Patients meeting DSM-IV for either Bipolar I, Bipolar II, Cyclothymic Disorder, or Bipolar Disorder NOS Patients on monotherapy treatment with lithium carbonate at steady state level for a minimum of two weeks prior to study treatment assignment Women are postmenopausal for at least 1 year, or surgically incapable of childbearing, or practicing an acceptable method of birth control (hormonal contraception, intrauterine device, or barrier with spermicide were acceptable) and not pregnant at baseline  Patients with a history of an acquired or hereditary neurologic disease, e.g., epilepsy or significant brain trauma Patients on depot medications, including but not limited to haloperidol, decanoate and Depo-Provera Patients who had taken acetazolamide, zonisamide, triamterene, dichlorphenamide, chronic antacids, or calcium supplements, or any medication associated with nephrolithiasis (kidney stone formation) in the month prior to beginning topiramate titration
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Bipolar Disorder Dyssomnias Bipolar disorder patients with sleep disturbance Meeting Diagnostic and Statistical Manual of Mental Disorders, 4th Text Revision (DSM-IV-TR; APA, 2000) diagnostic for bipolar disorder type 1 (established with the SCID: Structured Clinical Interview for DSM-IV) Being inter-episode throughout the experiment as defined by cutoffs widely used in previous research. On the basis that a drug-free group would likely be unfeasible and unrepresentative, participants will not be excluded on the basis of medications prescribed for bipolar disorder. Comorbidity will be allowed as long as bipolar disorder is the primary diagnosis. However, it is necessary to assess comorbidity for reporting purposes Participants who have a history of bipolar 1 or suicidal ideation must be under the care of a psychiatrist Experience distress related to significant sleep disturbance  Presence of an active and progressive physical illness (e.g., congestive heart failure, cancer, COPD) or neurological degenerative diseases (e.g., dementia, multiple sclerosis) directly related to the onset and course of insomnia Alcohol or drug abuse (except nicotine) within the past year Active posttraumatic stress disorder Evidence of sleep apnea, restless legs syndrome or periodic limb movements during sleep, or a circadian-based sleep disorder (e.g., delayed or advanced sleep phase syndrome) Patients who pose a current suicidal risk or homicidal risk (assessed by treating psychiatrist) or who have made a suicide attempt within the past 6 months Pharmacotherapy for sleep defined as the benzodiazepine and non-benzodiazepine hypnotics that operate via the GABA A receptor complex and are FDA approved for the treatment of insomnia, selective melatonin agonists, benzodiazepine anxiolytics and over the counter medications with proven efficacy such as melatonin or herbs such as St. Johns wort Use of certain medications known to alter sleep (e.g., steroids, theophylline, propranolol, antihistamines that cause drowsiness)
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Multiple System Atrophy Clinical diagnosis of probable MSA (Gilman, et al. 2008) Age ≥18, <80  Heart failure Liver disease Kidney failure Thyroid disease Sick sinus syndrome and/or significant ECG alterations Hyposodemia Treatment with diuretics Treatment with haloperidol and/or other antipsychotics Treatment with NSAIDs or corticosteroids Treatment with ACE inhibitors
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  SPINOCEREBELLAR ATAXIA 2 Molecular diagnosis of SCA2 (≥34 CAG in the ataxin-2 gene) Age ≥18, <80 SARA score ≥8  SARA score >32 Heart failure Liver disease Kidney failure Thyroid disease Sick sinus syndrome and/or significant ECG alterations Hyposodemia Treatment with diuretics Treatment with haloperidol and/or other antipsychotics Treatment with NSAIDs or corticosteroids
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 20.0-65.0,  Sleep Initiation and Maintenance Disorders Patient is diagnosed as a primary insomnia according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) Patients complaining of insomnia continuously for 4 weeks or longer Patient's usual bedtime is between 9 p.m. and 12 a.m. for the 4 week period prior to initial screening Patient on most occasions sleeps for a total of ≥3 and <6.5 hours over the 4 week period prior to initial screening Patient's usual wake time after sleep onset in a single night is ≥45 minutes per night for the 4 week period prior to initial screening Patients have a body weight of ≥45 kg and ≤85 kg, a BMI of ≥18.5 and <30  Patients with schizophrenia or manic-depressive psychosis Patients with insomnia caused by physical diseases including chronic obstructive pulmonary disease, bronchial asthma, fibrositis syndrome, chronic fatigue syndrome, rheumatic disease, climacteric disturbance, and dermatitis atopic Patients with circadian rhythm sleep disorder Patient works night shifts Patients with alcoholic sleep disorder Patients with alcohol or drug dependence or a history of these Patients with insomnia related with drugs including antiparkinson, antihypertensive, or steroid drugs Patients with sleep apnea syndrome Patients with restless legs syndrome or periodic limb movement disorder Patients with epileptic insomnia